The HIV and HBV Therapies Market Report 2022-2032: This report will prove valuable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Factors Such as Rising Prevalence of HIV and HBV, High Investment in R&D, and Growing Government Support Are Driving the Market Growth
Some of the major forces propelling the global HIV and HBV therapies market include rising prevalence of HIV and HBV, high investment in R&D, and growing government support. Robust government support for HIV and HBV therapies research is one of the major factors that propel the market growth. There is a need for significant collaborations among the pharmaceutical industry, foundations, patient advocacy organizations, academic and public researchers and financing programs, regulatory researchers and reimbursement organizations to identify and develop ...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS) - Drugs In Development, 2022, provides an overview of the Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline landscape.

HIV is a virus which attacks the immune system, and weakens ability to fight infections and disease. Symptoms include fever, sore throat, body rash, joint pain, muscle pain and swollen glands. The most common ways HIV is spread are by having vaginal or anal intercourse without a condom with someone who has HIV/AIDS, sharing needles or syringes with someone who has HIV/AIDS, being deeply punctured with a needle or surgical instrument contaminated with HIV and getting HIV-infected blood, semen, or vaginal secretions into open wounds or sores.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS) - Drugs In Development, 2022, provides comprehensive informa...

Summary

Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the HIV market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
- Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
- Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development stat...

Summary

GlobalData's clinical trial report, “AIDS - Related Cancer Global Clinical Trials Review, H2, 2018" provides an overview of AIDS - Related Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on AIDS - Related Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies t...

Summary

GlobalData's clinical trial report, “AIDS - Related Lymphoma Global Clinical Trials Review, H2, 2018" provides an overview of AIDS - Related Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on AIDS - Related Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strate...

Summary

GlobalData's clinical trial report, “AIDS Associated Dementia Global Clinical Trials Review, H2, 2018" provides an overview of AIDS Associated Dementia clinical trials scenario. This report provides top line data relating to the clinical trials on AIDS Associated Dementia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter str...

Summary

The "Digital Landscape: HIV", report analyzes digital activities undertaken by pharma in support of therapies for the treatment of HIV.

Key Highlights

- US Patients: US patient landscape is dominated by Gilead, ViiV and Janssen, with Gilead providing the most complete HIV digital offering. Gilead and ViiV provide the best unbranded support. Lack of pharma-sponsored social media initiatives that provide patients with a sense of community. Limited HIV mobile app support in the US from pharma, with Gilead providing the only HIV-specific offerings for patients.
- US HCPs: Many feature-rich brand sites available for US HCPs. ViiV and Gilead provide unbranded sites aimed at improving patient communication and care. Opportunities exist for the development or sponsorship of HIV-specific apps for US HCPs, that support patient management and treatment decisions.
- EUCAN Patients: Branded support only detected in Canada from ViiV and Gilead. Janssen provides the most local-language unbranded offerings across the 5EU, but no unbranded suppor...

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
HIV 1 Integrase (EC 2.7.7.) Overview 7
Therapeutics Development 8
HIV 1 Integrase (EC 2.7.7.) - Products under Development by Stage of Development 8
HIV 1 Integrase (EC 2.7.7.) - Products under Development by Therapy Area 9
HIV 1 Integrase (EC 2.7.7.) - Products under Development by Indication 10
HIV 1 Integrase (EC 2.7.7.) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
HIV 1 Integrase (EC 2.7.7.) - Products under Development by Companies 13
HIV 1 Integrase (EC 2.7.7.) - Products under Development by Universities/Institutes 15
HIV 1 Integrase (EC 2.7.7.) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
HIV 1 Integrase (EC 2.7.7.) - Companies Involved in Therapeutics Development 23
Critical Outcome Technologies Inc 23<...